{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:19:21Z","timestamp":1783635561893,"version":"3.55.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11095-025-03974-5","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T01:14:51Z","timestamp":1764897291000},"page":"1763-1783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Role of Nanostructured Lipid Carriers in Overcoming Cancer Treatment Challenges"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6717-0263","authenticated-orcid":false,"given":"Revati T.","family":"Deore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"3974_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01213-z","volume":"14","author":"L Lin","year":"2021","unstructured":"Lin L, Li Z, Yan L, Liu Y, Yang H, Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990\u20132019. J Hematol Oncol. 2021;14:1\u201324.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3974_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"3974_CR3","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663\u201376.","journal-title":"Mol Biol Rep"},{"issue":"2","key":"3974_CR4","volume":"6","author":"A Pulumati","year":"2023","unstructured":"Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RV. Technological advancements in cancer diagnostics: improvements and limitations. Cancer Rep. 2023;6(2):e1764.","journal-title":"Cancer Rep"},{"key":"3974_CR5","doi-asserted-by":"crossref","unstructured":"Mao X, Wu S, Huang D, Li C. Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy. Acta Pharmaceutica Sinica B. 2024;14(7):2901\u201326.","DOI":"10.1016\/j.apsb.2024.03.006"},{"key":"3974_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211067083","volume":"9","author":"ZD Kifle","year":"2021","unstructured":"Kifle ZD, Tadele M, Alemu E, Gedamu T, Ayele AG. A recent development of new therapeutic agents and novel drug targets for cancer treatment. SAGE Open Med. 2021;9:20503121211067083.","journal-title":"SAGE Open Med"},{"issue":"5","key":"3974_CR7","doi-asserted-by":"publisher","DOI":"10.2174\/0122106812316387240822075859","volume":"14","author":"A Saha","year":"2024","unstructured":"Saha A, Chauhan SB, Singh I. Targeted drug delivery with lipid-based nanoparticles: innovations for improved cancer therapy. Nanosci Nanotechnol-Asia. 2024;14(5):E22106812316387.","journal-title":"Nanosci Nanotechnol-Asia"},{"issue":"6","key":"3974_CR8","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3390\/pharmaceutics15061593","volume":"15","author":"C Viegas","year":"2023","unstructured":"Viegas C, Patr\u00edcio AB, Prata JM, Nadhman A, Chintamaneni PK, Fonte P. Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review. Pharmaceutics. 2023;15(6):1593.","journal-title":"Pharmaceutics"},{"issue":"9","key":"3974_CR9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jsps.2021.07.015","volume":"29","author":"M Elmowafy","year":"2021","unstructured":"Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm J. 2021;29(9):999\u20131012.","journal-title":"Saudi Pharm J"},{"issue":"29","key":"3974_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.867655","volume":"12","author":"VP Chavda","year":"2022","unstructured":"Chavda VP, Patel AB, Mistry KJ, Suthar SF, Wu ZX, Chen ZS, et al. Nano-drug delivery systems entrapping natural bioactive compounds for cancer: recent progress and future challenges. Front Oncol. 2022;12(29):867655.","journal-title":"Front Oncol"},{"key":"3974_CR11","doi-asserted-by":"crossref","unstructured":"Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit Rev\u2122 Therapeutic Drug Carrier Syst. 2009;26(6):523\u201380.","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10"},{"key":"3974_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"A Akbarzadeh","year":"2013","unstructured":"Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:1\u20139.","journal-title":"Nanoscale Res Lett"},{"key":"3974_CR13","doi-asserted-by":"crossref","unstructured":"Harshita, Barkat MA, Das SS, Pottoo FH, Beg S, Rahman Z. Lipid-based nanosystem as intelligent carriers for versatile drug delivery applications. Curr Pharm Design. 2020;26(11):1167\u201380.","DOI":"10.2174\/1381612826666200206094529"},{"issue":"7","key":"3974_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.587997","volume":"30","author":"S Scioli Montoto","year":"2020","unstructured":"Scioli Montoto S, Muraca G, Ruiz ME. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Front Mol Biosci. 2020;30(7):587997.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"3974_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/molecules27010289","volume":"27","author":"SN Syed Azhar","year":"2022","unstructured":"Syed Azhar SN, Ashari SE, Zainuddin N, Hassan M. Nanostructured lipid carriers-hydrogels system for drug delivery: Nanohybrid technology perspective. Molecules. 2022;27(1):289.","journal-title":"Molecules"},{"issue":"1","key":"3974_CR16","first-page":"4687959","volume":"2023","author":"AK Mahor","year":"2023","unstructured":"Mahor AK, Singh PP, Gupta R, Bhardwaj P, Rathore P, Kishore A, et al. Nanostructured lipid carriers for improved delivery of therapeutics via the oral route. J Nanotechnol. 2023;2023(1):4687959.","journal-title":"J Nanotechnol"},{"issue":"4","key":"3974_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/jnt5040012","volume":"5","author":"MD Queiroz","year":"2024","unstructured":"Queiroz MD, Muehlmann LA. Characteristics and preparation of solid lipid nanoparticles and nanostructured lipid carriers. J Nanotheranostics. 2024;5(4):188\u2013211.","journal-title":"J Nanotheranostics"},{"issue":"1","key":"3974_CR18","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6(1):286.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3974_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrd1632","volume":"4","author":"VP Torchilin","year":"2005","unstructured":"Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145\u201360.","journal-title":"Nat Rev Drug Discov"},{"issue":"1\u20132","key":"3974_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijpharm.2017.04.076","volume":"526","author":"C Tetyczka","year":"2017","unstructured":"Tetyczka C, Griesbacher M, Absenger-Novak M, Fr\u00f6hlich E, Roblegg E. Development of nanostructured lipid carriers for intraoral delivery of Domperidone. Int J Pharm. 2017;526(1\u20132):188\u201398.","journal-title":"Int J Pharm"},{"issue":"51","key":"3974_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jddst.2019.02.017","volume":"1","author":"VR Salvi","year":"2019","unstructured":"Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Deliv Sci Technol. 2019;1(51):255\u201367.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"3974_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejps.2012.05.010","volume":"47","author":"S Das","year":"2012","unstructured":"Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47(1):139\u201351.","journal-title":"Eur J Pharm Sci"},{"issue":"321","key":"3974_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jconrel.2020.02.020","volume":"10","author":"M Agrawal","year":"2020","unstructured":"Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Patel RJ, et al. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release. 2020;10(321):372\u2013415.","journal-title":"J Control Release"},{"issue":"1","key":"3974_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/187221013804484827","volume":"7","author":"CL Fang","year":"2013","unstructured":"Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Patents Nanotechnol. 2013;7(1):41\u201355.","journal-title":"Recent Patents Nanotechnol"},{"key":"3974_CR25","doi-asserted-by":"crossref","unstructured":"Harshita, Barkat MA, Rizwanullah M, Beg S, Pottoo FH, Siddiqui S, Ahmad FJ. Paclitaxel-loaded nanolipidic carriers with improved oral bioavailability and anticancer activity against human liver carcinoma. AAPS PharmSciTech. 2019;20(2):87.","DOI":"10.1208\/s12249-019-1304-4"},{"issue":"3","key":"3974_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1208\/s12249-019-1337-8","volume":"20","author":"S Talegaonkar","year":"2019","unstructured":"Talegaonkar S, Bhattacharyya A. Potential of lipid nanoparticles (SLNs and NLCs) in enhancing oral bioavailability of drugs with poor intestinal permeability. AAPS PharmSciTech. 2019;20(3):121.","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"3974_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3109\/10717544.2014.898110","volume":"22","author":"B Gaba","year":"2015","unstructured":"Gaba B, Fazil M, Ali A, Baboota S, Sahni JK, Ali J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv. 2015;22(6):691\u2013700.","journal-title":"Drug Deliv"},{"key":"3974_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1208\/s12249-011-9733-8","volume":"13","author":"A Chinsriwongkul","year":"2012","unstructured":"Chinsriwongkul A, Chareanputtakhun P, Ngawhirunpat T, Rojanarata T, Sila-on W, Ruktanonchai U, et al. Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug. AAPS PharmSciTech. 2012;13:150\u20138.","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"3974_CR29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3109\/10717544.2013.835007","volume":"20","author":"J Luan","year":"2013","unstructured":"Luan J, Zhang D, Hao L, Li C, Qi L, Guo H, et al. Design and characterization of Amoitone B-loaded nanostructured lipid carriers for controlled drug release. Drug Delivery. 2013;20(8):324\u201330.","journal-title":"Drug Delivery"},{"issue":"19","key":"3974_CR30","volume":"1","author":"FS Anarjan","year":"2019","unstructured":"Anarjan FS. Active targeting drug delivery nanocarriers: ligands. Nano-Struct Nano-Objects. 2019;1(19):100370.","journal-title":"Nano-Struct Nano-Objects"},{"issue":"64","key":"3974_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","volume":"1","author":"W Mehnert","year":"2012","unstructured":"Mehnert W, M\u00e4der K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;1(64):83\u2013101.","journal-title":"Adv Drug Deliv Rev"},{"issue":"163","key":"3974_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejpb.2021.04.007","volume":"1","author":"MK Iqubal","year":"2021","unstructured":"Iqubal MK, Iqubal A, Imtiyaz K, Rizvi MM, Gupta MM, Ali J, et al. Combinatorial lipid-nanosystem for dermal delivery of 5-fluorouracil and resveratrol against skin cancer: Delineation of improved dermatokinetics and epidermal drug deposition enhancement analysis. Eur J Pharm Biopharm. 2021;1(163):223\u201339.","journal-title":"Eur J Pharm Biopharm"},{"issue":"108","key":"3974_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejpb.2016.08.001","volume":"1","author":"S Doktorovova","year":"2016","unstructured":"Doktorovova S, Kova\u010devi\u0107 AB, Garcia ML, Souto EB. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2016;1(108):235\u201352.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"3974_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijpharm.2013.12.006","volume":"461","author":"LM Negi","year":"2014","unstructured":"Negi LM, Jaggi M, Talegaonkar S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int J Pharm. 2014;461(1\u20132):403\u201310.","journal-title":"Int J Pharm"},{"issue":"6","key":"3974_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/nano7060122","volume":"7","author":"Q Li","year":"2017","unstructured":"Li Q, Cai T, Huang Y, Xia X, Cole SP, Cai Y. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials. 2017;7(6):122.","journal-title":"Nanomaterials"},{"issue":"2","key":"3974_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ijpharm.2010.02.008","volume":"390","author":"Y Zheng","year":"2010","unstructured":"Zheng Y, Yu B, Weecharangsan W, Piao L, Darby M, Mao Y, et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7\u03b1-APTADD to breast cancer cells. Int J Pharm. 2010;390(2):234\u201341.","journal-title":"Int J Pharm"},{"issue":"264","key":"3974_CR37","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","volume":"28","author":"C Tapeinos","year":"2017","unstructured":"Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;28(264):306\u201332.","journal-title":"J Control Release"},{"issue":"108","key":"3974_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ejpb.2016.07.026","volume":"1","author":"VM Ghate","year":"2016","unstructured":"Ghate VM, Lewis SA, Prabhu P, Dubey A, Patel N. Nanostructured lipid carriers for the topical delivery of tretinoin. Eur J Pharm Biopharm. 2016;1(108):253\u201361.","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"3974_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.31083\/ph.2009.9084","volume":"64","author":"M Muchow","year":"2009","unstructured":"Muchow M, Schmitz EI, Despatova N, Maincent P, M\u00fcller RH. Omega-3 fatty acids-loaded lipid nanoparticles for patient-convenient oral bioavailability enhancement. Pharmazie. 2009;64(8):499\u2013504.","journal-title":"Pharmazie"},{"key":"3974_CR40","doi-asserted-by":"crossref","unstructured":"Atapour-Mashhad H, Tayarani-Najaran Z, Golmohammadzadeh S. Preparation and characterization of novel nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN) containing coenzyme Q10 as potent antioxidants and antityrosinase agents. Heliyon. 2024;10(11):e31429.","DOI":"10.1016\/j.heliyon.2024.e31429"},{"issue":"3","key":"3974_CR41","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/pharmaceutics15030951","volume":"15","author":"D Santonocito","year":"2023","unstructured":"Santonocito D, Barbagallo I, Distefano A, Sferrazzo G, Vivero-Lopez M, Sarpietro MG, et al. Nanostructured lipid carriers aimed to the ocular delivery of mangiferin: In Vitro evidence. Pharmaceutics. 2023;15(3):951.","journal-title":"Pharmaceutics"},{"issue":"10","key":"3974_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jconrel.2014.10.033","volume":"197","author":"G Gainza","year":"2015","unstructured":"Gainza G, Bonafonte DC, Moreno B, Aguirre JJ, Gutierrez FB, Villullas S, et al. The topical administration of rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) improves healing in a porcine full-thickness excisional wound model. J Control Release. 2015;197(10):41\u20137.","journal-title":"J Control Release"},{"issue":"3","key":"3974_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1208\/s12249-015-0391-0","volume":"17","author":"M Elmowafy","year":"2016","unstructured":"Elmowafy M, Samy A, Raslan MA, Salama A, Said RA, Abdelaziz AE, et al. Enhancement of bioavailability and pharmacodynamic effects of thymoquinone via nanostructured lipid carrier (NLC) formulation. AAPS PharmSciTech. 2016;17(3):663\u201372.","journal-title":"AAPS PharmSciTech"},{"issue":"1\u20132","key":"3974_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ijpharm.2011.05.044","volume":"415","author":"R Tiwari","year":"2011","unstructured":"Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: Comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. 2011;415(1\u20132):232\u201343.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"3974_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ijpharm.2011.07.040","volume":"419","author":"J Pardeike","year":"2011","unstructured":"Pardeike J, Weber S, Haber T, Wagner J, Zarfl HP, Plank H, et al. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm. 2011;419(1\u20132):329\u201338.","journal-title":"Int J Pharm"},{"key":"3974_CR46","first-page":"586","volume":"30","author":"A Huguet-Casquero","year":"2020","unstructured":"Huguet-Casquero A, Xu Y, Gainza E, Pedraz JL, Beloqui A. Oral delivery of oleuropein-loaded lipid nanocarriers alleviates inflammation and oxidative stress in acute colitis. Int J Pharm. 2020;30:586.","journal-title":"Int J Pharm"},{"issue":"1","key":"3974_CR47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejpb.2016.10.011","volume":"109","author":"S Khan","year":"2016","unstructured":"Khan S, Shaharyar M, Fazil M, Hassan MQ, Baboota S, Ali J. Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement. Eur J Pharm Biopharm. 2016;109(1):149\u201357.","journal-title":"Eur J Pharm Biopharm"},{"key":"3974_CR48","first-page":"117","volume":"9","author":"YK Lin","year":"2010","unstructured":"Lin YK, Huang ZR, Zhuo RZ, Fang JY. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomed. 2010;9:117\u201328.","journal-title":"Int J Nanomed"},{"issue":"1","key":"3974_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.colsurfb.2013.08.032","volume":"113","author":"M Sun","year":"2014","unstructured":"Sun M, Nie S, Pan X, Zhang R, Fan Z, Wang S. Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. Colloids Surf B Biointerfaces. 2014;113(1):15\u201324.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"108","key":"3974_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2019.110412","volume":"1","author":"I Lacatusu","year":"2020","unstructured":"Lacatusu I, Istrati D, Bordei N, Popescu M, Seciu AM, Panteli LM, et al. Synergism of plant extract and vegetable oils-based lipid nanocarriers: Emerging trends in development of advanced cosmetic prototype products. Mater Sci Eng, C. 2020;1(108):110412.","journal-title":"Mater Sci Eng, C"},{"key":"3974_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11051-020-04848-0","volume":"22","author":"B Subramaniam","year":"2020","unstructured":"Subramaniam B, Siddik ZH, Nagoor NH. Optimization of nanostructured lipid carriers: understanding the types, designs, and parameters in the process of formulations. J Nanopart Res. 2020;22:1\u201329.","journal-title":"J Nanopart Res"},{"issue":"2","key":"3974_CR52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jconrel.2008.02.011","volume":"128","author":"V Teeranachaideekul","year":"2008","unstructured":"Teeranachaideekul V, Boonme P, Souto EB, M\u00fcller RH, Junyaprasert VB. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC. J Control Release. 2008;128(2):134\u201341.","journal-title":"J Control Release"},{"key":"3974_CR53","doi-asserted-by":"crossref","unstructured":"Patel P, Hanini A, Shah A, Patel D, Patel S, Bhatt P, Pathak YV. Surface modification of nanoparticles for targeted drug delivery. Springer International Publishing; 2019.","DOI":"10.1007\/978-3-030-06115-9_2"},{"issue":"23","key":"3974_CR54","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.2174\/1385272820666161031161101","volume":"21","author":"DP Gaspar","year":"2017","unstructured":"Gaspar DP, Faria V, Quintas JP, Almeida AJ. Targeted delivery of lipid nanoparticles by means of surface chemical modification. Curr Org Chem. 2017;21(23):2360\u201375.","journal-title":"Curr Org Chem"},{"issue":"2","key":"3974_CR55","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.colsurfb.2009.09.033","volume":"75","author":"S Doktorovov\u00e1","year":"2010","unstructured":"Doktorovov\u00e1 S, Ara\u00fajo J, Garcia ML, Rakovsk\u00fd E, Souto EB. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf, B. 2010;75(2):538\u201342.","journal-title":"Colloids Surf, B"},{"issue":"5","key":"3974_CR56","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/10837450.2022.2084554","volume":"27","author":"J Akbari","year":"2022","unstructured":"Akbari J, Saeedi M, Ahmadi F, Hashemi SM, Babaei A, Yaddollahi S, et al. Solid lipid nanoparticles and nanostructured lipid carriers: A review of the methods of manufacture and routes of administration. Pharm Dev Technol. 2022;27(5):525\u201344.","journal-title":"Pharm Dev Technol"},{"issue":"2","key":"3974_CR57","first-page":"1","volume":"7","author":"A Sharma","year":"2018","unstructured":"Sharma A, Baldi A. Nanostructured lipid carriers: a review. J Developing Drugs. 2018;7(2):1\u20135.","journal-title":"J Developing Drugs"},{"issue":"1\u20132","key":"3974_CR58","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","volume":"366","author":"J Pardeike","year":"2009","unstructured":"Pardeike J, Hommoss A, M\u00fcller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1\u20132):170\u201384.","journal-title":"Int J Pharm"},{"key":"3974_CR59","doi-asserted-by":"crossref","unstructured":"Mall J, Naseem N, Haider MF, Rahman MA, Khan S, Siddiqui SN. Nanostructured lipid carriers as a drug delivery system: A comprehensive review with therapeutic applications. Intelligent Pharmacy. 2024 Sep 23.","DOI":"10.1016\/j.ipha.2024.09.005"},{"issue":"6(2)","key":"3974_CR60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1517\/17425240802712590","volume":"1","author":"S Doktorovova","year":"2009","unstructured":"Doktorovova S, Souto EB. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: a comprehensive review. Expert Opin Drug Deliv. 2009;1(6(2)):165\u201376.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"3974_CR61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3109\/21691401.2014.909822","volume":"44","author":"P Jaiswal","year":"2016","unstructured":"Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells, Nanomed, Biotechnol. 2016;44(1):27\u201340.","journal-title":"Artif Cells, Nanomed, Biotechnol"},{"key":"3974_CR62","doi-asserted-by":"crossref","unstructured":"Vitorino C, Almeida A, Sousa J, Lamarche I, Gobin P, Marchand S, Couet W, Olivier JC, Pais A. Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies. Eur J Pharm Biopharm. 2014 Feb 1;86(2):133\u201344.","DOI":"10.1016\/j.ejpb.2013.12.004"},{"issue":"103","key":"3974_CR63","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","volume":"1","author":"A Khosa","year":"2018","unstructured":"Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;1(103):598\u2013613.","journal-title":"Biomed Pharmacother"},{"issue":"28","key":"3974_CR64","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jconrel.2013.11.023","volume":"174","author":"A Vilella","year":"2014","unstructured":"Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, Vandelli MA, et al. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. J Control Release. 2014;174(28):195\u2013201.","journal-title":"J Control Release"},{"issue":"11","key":"3974_CR65","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM. Drug transport across the blood\u2013brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959\u201372.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3974_CR66","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.2147\/IJN.S36257","volume":"9","author":"M Fang","year":"2012","unstructured":"Fang M, Jin Y, Bao W, Gao H, Xu M, Wang D, et al. In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. Int J Nanomed. 2012;9:5395\u2013404.","journal-title":"Int J Nanomed"},{"key":"3974_CR67","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1023\/A:1018888927852","volume":"16","author":"S Yang","year":"1999","unstructured":"Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16:751\u20137.","journal-title":"Pharm Res"},{"key":"3974_CR68","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","volume":"148","author":"F Danhier","year":"2010","unstructured":"Danhier F, Feron O, Pr\u00e9at V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148:135\u201346.","journal-title":"J Control Release"},{"key":"3974_CR69","doi-asserted-by":"crossref","unstructured":"Tsai MJ, Wu PC, Huang Y Bin, Chang JS, Lin CL, Tsai YH, et al. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int J Pharm. 2012 Feb 28;423(2):461\u201370.","DOI":"10.1016\/j.ijpharm.2011.12.009"},{"key":"3974_CR70","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1959\u201372.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3974_CR71","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1208\/s12249-010-9563-0","volume":"12","author":"S Das","year":"2011","unstructured":"Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12:62\u201376.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"3974_CR72","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ejpb.2008.05.008","volume":"70","author":"JY Fang","year":"2008","unstructured":"Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70(2):633\u201340.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"3974_CR73","first-page":"102","volume":"22","author":"HW Zhang","year":"2017","unstructured":"Zhang HW, Dang Q, Zhang ZW, Wu FS. Development, characterization and evaluation of doxorubicin nanostructured lipid carriers for prostate cancer. J buon. 2017;22(1):102\u201311.","journal-title":"J buon"},{"issue":"5","key":"3974_CR74","first-page":"375","volume":"61","author":"M \u00dcner","year":"2006","unstructured":"\u00dcner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Die Pharmazie-an Int J Pharm Sci. 2006;61(5):375\u201386.","journal-title":"Die Pharmazie-an Int J Pharm Sci"},{"issue":"1","key":"3974_CR75","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/463732","volume":"2013","author":"PC Chen","year":"2013","unstructured":"Chen PC, Huang JW, Pang J. An investigation of optimum NLC-sunscreen formulation using Taguchi analysis. J Nanomater. 2013;2013(1):463732.","journal-title":"J Nanomater"},{"issue":"5","key":"3974_CR76","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/polym15051123","volume":"15","author":"M Elmowafy","year":"2023","unstructured":"Elmowafy M, Shalaby K, Elkomy MH, Alsaidan OA, Gomaa HA, Abdelgawad MA, et al. Polymeric nanoparticles for delivery of natural bioactive agents: recent advances and challenges. Polymers. 2023;15(5):1123.","journal-title":"Polymers"},{"issue":"3","key":"3974_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030288","volume":"12","author":"M Haider","year":"2020","unstructured":"Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics. 2020;12(3):288.","journal-title":"Pharmaceutics"},{"issue":"226","key":"3974_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2023.113309","volume":"1","author":"LR Nicoleti","year":"2023","unstructured":"Nicoleti LR, Di Filippo LD, Duarte JL, Luiz MT, S\u00e1bio RM, Chorilli M. Development, characterization and in vitro cytotoxicity of kaempferol-loaded nanostructured lipid carriers in glioblastoma multiforme cells. Colloids Surf, B. 2023;1(226):113309.","journal-title":"Colloids Surf, B"},{"issue":"8","key":"3974_CR79","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1080\/1061186X.2023.2243403","volume":"31","author":"F Fatima Qizilbash","year":"2023","unstructured":"Fatima Qizilbash F, Sartaj A, Qamar Z, Kumar S, Imran M, Mohammed Y, et al. Nanotechnology revolutionises breast cancer treatment: harnessing lipid-based nanocarriers to combat cancer cells. J Drug Target. 2023;31(8):794\u2013816.","journal-title":"J Drug Target"},{"key":"3974_CR80","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2024047670","author":"K Chaudhary","year":"2025","unstructured":"Chaudhary K, Rajora A. Elevating therapeutic penetration: innovations in drug delivery for enhanced permeation and skin cancer management. Crit Rev\u2122 Ther Drug Carrier Syst. 2025. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2024047670.","journal-title":"Crit Rev\u2122 Ther Drug Carrier Syst"},{"key":"3974_CR81","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.2147\/IJN.S305851","volume":"29","author":"S Cunha","year":"2021","unstructured":"Cunha S, Forbes B, Sousa Lobo JM, Silva AC. Improving drug delivery for Alzheimer\u2019s disease through nose-to-brain delivery using nanoemulsions, nanostructured lipid carriers (NLC) and in situ hydrogels. Int J Nanomed. 2021;29:4373\u201390.","journal-title":"Int J Nanomed"},{"issue":"1","key":"3974_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2021.102509","volume":"296","author":"B Dutta","year":"2021","unstructured":"Dutta B, Barick KC, Hassan PA. Recent advances in active targeting of nanomaterials for anticancer drug delivery. Adv Colloid Interface Sci. 2021;296(1):102509.","journal-title":"Adv Colloid Interface Sci"},{"issue":"39","key":"3974_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2022.102915","volume":"1","author":"VR Shinde","year":"2022","unstructured":"Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagn Photodyn Ther. 2022;1(39):102915.","journal-title":"Photodiagn Photodyn Ther"},{"key":"3974_CR84","doi-asserted-by":"crossref","unstructured":"Kumar R, Dkhar DS, Kumari R, Divya, Mahapatra S, Srivastava A, Dubey VK, Chandra P. Ligand conjugated lipid\u2010based nanocarriers for cancer theranostics. Biotechnol Bioeng. 2022;119(11):3022\u201343.","DOI":"10.1002\/bit.28205"},{"key":"3974_CR85","first-page":"1","volume":"10","author":"LM Li","year":"2024","unstructured":"Li LM, Xie YP, Qin YR, Chu HP, Xie H, Zang DJ, et al. Tumor microenvironment-responsive drug self-delivery systems to treat cancer and overcome MDR. Rare Met. 2024;10:1\u201333.","journal-title":"Rare Met"},{"issue":"4","key":"3974_CR86","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3390\/pharmaceutics14040836","volume":"14","author":"BA Witika","year":"2022","unstructured":"Witika BA, Poka MS, Demana PH, Matafwali SK, Melamane S, Malungelo Khamanga SM, et al. Lipid-based nanocarriers for neurological disorders: a review of the state-of-the-art and therapeutic success to date. Pharmaceutics. 2022;14(4):836.","journal-title":"Pharmaceutics"},{"issue":"8","key":"3974_CR87","volume":"16","author":"KR Santhanakrishnan","year":"2024","unstructured":"Santhanakrishnan KR, Koilpillai J, Narayanasamy D. PEGylation in pharmaceutical development: current status and emerging trends in macromolecular and immunotherapeutic drugs. Cureus. 2024;16(8):e66669.","journal-title":"Cureus"},{"issue":"6","key":"3974_CR88","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/pharmaceutics15061668","volume":"15","author":"MF Zaky","year":"2023","unstructured":"Zaky MF, Hammady TM, Gad S, Alattar A, Alshaman R, Hegazy A, et al. Influence of surface-modification via PEGylation or chitosanization of lipidic nanocarriers on in vivo pharmacokinetic\/pharmacodynamic profiles of apixaban. Pharmaceutics. 2023;15(6):1668.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3974_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114643","volume":"162","author":"C Duan","year":"2023","unstructured":"Duan C, Yu M, Xu J, Li BY, Zhao Y, Kankala RK. Overcoming cancer multi-drug resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed Pharmacother. 2023;162(1):114643.","journal-title":"Biomed Pharmacother"},{"issue":"179","key":"3974_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117327","volume":"1","author":"L Gao","year":"2024","unstructured":"Gao L, Meng F, Yang Z, Lafuente-Merchan M, Fern\u00e1ndez LM, Cao Y, et al. Nano-drug delivery system for the treatment of multidrug-resistant breast cancer: Current status and future perspectives. Biomed Pharmacother. 2024;1(179):117327.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"3974_CR91","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/pharmaceutics12020142","volume":"12","author":"NE Eleraky","year":"2020","unstructured":"Eleraky NE, Allam A, Hassan SB, Omar MM. Nanomedicine fight against antibacterial resistance: an overview of the recent pharmaceutical innovations. Pharmaceutics. 2020;12(2):142.","journal-title":"Pharmaceutics"},{"issue":"279","key":"3974_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119576","volume":"15","author":"A Mahoutforoush","year":"2021","unstructured":"Mahoutforoush A, Solouk A, Hamishehkar H, Nazarpak MH, Abbaspour-Ravasjani S. Novel decorated nanostructured lipid carrier for simultaneous active targeting of three anti-cancer agents. Life Sci. 2021;15(279):119576.","journal-title":"Life Sci"},{"issue":"345","key":"3974_CR93","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jconrel.2022.03.019","volume":"1","author":"M Farshbaf","year":"2022","unstructured":"Farshbaf M, Mojarad-Jabali S, Hemmati S, Khosroushahi AY, Motasadizadeh H, Zarebkohan A, et al. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers. J Control Release. 2022;1(345):371\u201384.","journal-title":"J Control Release"},{"issue":"14","key":"3974_CR94","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.3390\/molecules27144553","volume":"27","author":"Y Ma","year":"2022","unstructured":"Ma Y, Liu J, Cui X, Hou J, Yu F, Wang J, et al. Hyaluronic acid modified nanostructured lipid carrier for targeting delivery of kaempferol to NSCLC: Preparation, optimization, characterization, and performance evaluation in vitro. Molecules. 2022;27(14):4553.","journal-title":"Molecules"},{"key":"3974_CR95","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1007\/s13346-020-00866-6","volume":"11","author":"S Rawal","year":"2021","unstructured":"Rawal S, Bora V, Patel B, Patel M. Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small cell lung cancer. Drug Deliv Transl Res. 2021;11:2030\u201351.","journal-title":"Drug Deliv Transl Res"},{"issue":"36","key":"3974_CR96","doi-asserted-by":"publisher","first-page":"22840","DOI":"10.1021\/acsomega.0c02072","volume":"5","author":"JY Wang","year":"2020","unstructured":"Wang JY, Song YQ, Peng J, Luo HL. Nanostructured lipid carriers delivering Sorafenib to enhance immunotherapy induced by doxorubicin for effective esophagus cancer therapy. ACS Omega. 2020;5(36):22840\u20136.","journal-title":"ACS Omega"},{"issue":"1","key":"3974_CR97","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ijpharm.2013.03.036","volume":"454","author":"H Shete","year":"2013","unstructured":"Shete H, Chatterjee S, De A, Patravale V. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int J Pharm. 2013;454(1):584\u201392.","journal-title":"Int J Pharm"},{"issue":"592","key":"3974_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120029","volume":"5","author":"S Moraes","year":"2021","unstructured":"Moraes S, Marinho A, Lima S, Granja A, Ara\u00fajo JP, Reis S, et al. Targeted nanostructured lipid carriers for doxorubicin oral delivery. Int J Pharm. 2021;5(592):120029.","journal-title":"Int J Pharm"},{"key":"3974_CR99","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12247-014-9187-0","volume":"9","author":"R Velmurugan","year":"2014","unstructured":"Velmurugan R, Selvamuthukumar S. In vivo antitumor activity of a novel orally bioavailable ifosfamide nanostructured lipid carrier against Dalton\u2019s ascitic lymphoma. J Pharm Innov. 2014;9:203\u201311.","journal-title":"J Pharm Innov"},{"issue":"1\u20132","key":"3974_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2014.03.056","volume":"468","author":"HK Shete","year":"2014","unstructured":"Shete HK, Selkar N, Vanage GR, Patravale VB. Tamoxifen nanostructured lipid carriers: enhanced in vivo antitumor efficacy with reduced adverse drug effects. Int J Pharm. 2014;468(1\u20132):1\u20134.","journal-title":"Int J Pharm"},{"issue":"2","key":"3974_CR101","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.canlet.2012.07.002","volume":"334","author":"XY Yang","year":"2013","unstructured":"Yang XY, Li YX, Li M, Zhang L, Feng LX, Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett. 2013;334(2):338\u201345.","journal-title":"Cancer Lett"},{"issue":"9","key":"3974_CR102","doi-asserted-by":"publisher","first-page":"129936","DOI":"10.1016\/j.bbagen.2021.129936","volume":"1865","author":"M Rizwanullah","year":"2021","unstructured":"Rizwanullah M, Ahmad MZ, Garg A, Ahmad J. Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application. Biochimica et Biophysica Acta (BBA)-General Subjects. 2021;1865(9):129936.","journal-title":"Biochimica et Biophysica Acta (BBA)-General Subjects"},{"key":"3974_CR103","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40005-020-00473-0","volume":"50","author":"E Atlihan-Gundogdu","year":"2020","unstructured":"Atlihan-Gundogdu E, Ilem-Ozdemir D, Ekinci M, Ozgenc E, Demir ES, S\u00e1nchez-Dengra B, et al. Recent developments in cancer therapy and diagnosis. J Pharm Investig. 2020;50:349\u201361.","journal-title":"J Pharm Investig"},{"key":"3974_CR104","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1007\/s11095-014-1436-x","volume":"31","author":"R Savla","year":"2014","unstructured":"Savla R, Garbuzenko OB, Chen S, Rodriguez-Rodriguez L, Minko T. Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy. Pharm Res. 2014;31:3487\u2013502.","journal-title":"Pharm Res"},{"issue":"just accepted","key":"3974_CR105","first-page":"1","volume":"15","author":"N Nehal","year":"2024","unstructured":"Nehal N, Rohilla A, Sartaj A, Baboota S, Ali J. Folic acid modified precision nanocarriers: charting new frontiers in breast cancer management beyond conventional therapies. J Drug Targeting. 2024;15(just accepted):1\u201333.","journal-title":"J Drug Targeting"},{"issue":"2","key":"3974_CR106","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","volume":"18","author":"J Majumder","year":"2021","unstructured":"Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18(2):205\u201327.","journal-title":"Expert Opin Drug Deliv"},{"issue":"18_Supplement","key":"3974_CR107","first-page":"5074s","volume":"51","author":"SA Rosenberg","year":"1991","unstructured":"Rosenberg SA. Immunotherapy and gene therapy of cancer. Cancer Res. 1991;51(18_Supplement):5074s\u20139s.","journal-title":"Cancer Res"},{"issue":"1","key":"3974_CR108","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3974_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124835","volume":"666","author":"H-E Kim","year":"2024","unstructured":"Kim H-E, Na Y-G, Jin M, Song B, Yun T-S, Hwang Y-R, et al. Fabrication and evaluation of chitosan-coated nanostructured lipid carriers for co-delivery of paclitaxel and PD-L1 siRNA. Int J Pharm. 2024;666:124835.","journal-title":"Int J Pharm"},{"issue":"17","key":"3974_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/asia.202500180","volume":"20","author":"S Patra","year":"2025","unstructured":"Patra S, Patra D, Dey J. Camptothecin-loaded surface-modified nanostructured lipid carriers consisting of L-cysteine- and L-cystine-derived lipids: physicochemical characterization and in vitro evaluation. Chem Asian J. 2025;20(17):e00180.","journal-title":"Chem Asian J"},{"issue":"1s","key":"3974_CR111","doi-asserted-by":"publisher","first-page":"225s","DOI":"10.18433\/jpps30117","volume":"21","author":"J Emami","year":"2018","unstructured":"Emami J, Yousefian H, Sadeghi H. Targeted nanostructured lipid carrier for brain delivery of artemisinin: design, preparation, characterization, optimization and cell toxicity. J Pharm Pharm Sci: Publ Canadian Soc Pharm Sci, Societe canadienne des sciences pharmaceutiques. 2018;21(1s):225s\u201341s.","journal-title":"J Pharm Pharm Sci: Publ Canadian Soc Pharm Sci, Societe canadienne des sciences pharmaceutiques"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03974-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03974-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03974-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:01:21Z","timestamp":1783634481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03974-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3974"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03974-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declare about no known competing financial conflicts or personal relationship that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}